A previous study by Chaib et al. reported that the coactivation of STAT3 and YAP signaling increased resistance to epidermal growth factor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in EGFR-mutated NSCLC [38]. This evidence concerns the gene YAP1 and non-small cell lung carcinoma.